| Carver Living Center | |
| 303 East Carver Street, Durham, North Carolina 27704 | |
| (919) 471-3558 | |
| Name | Carver Living Center |
|---|---|
| Location | 303 East Carver Street, Durham, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 232 |
| Occupancy Rate | 64.48% |
| Medicare ID (CCN) | 345434 |
| Legal Business Name | Carver Healthcare Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1669821336 |
| Organization Name | CARVER HEALTHCARE LLC |
| Doing Business As | CARVER LIVING CENTER |
| Address | 303 E Carver St, Durham, NC 27704 |
| Phone Number | 919-471-3558 |
News Archive
Human dihydroorotate dehydrogenase(DHODH) is a viable target for the development of therapeutics to treat cancer andimmunological diseases, such asrheumatoid arthritis(RA), psoriasis andmultiple sclerosis(MS).
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
Highlights from today's headlines include the latest political developments surrounding health reform as well as news about California's health insurance premium rates.
An innovative new medical program in Queensland will use the latest technology to help treat children living in remote Indigenous communities.
› Verified 8 days ago
| NPI Number | 1851336754 |
| Organization Name | DURHAM LIMITED PARTNERSHIP III |
| Doing Business As | CARVER LIVING CENTER |
| Address | 303 E. Carver Street, Durham, NC 27704 |
| Phone Number | 919-471-3558 |
News Archive
Human dihydroorotate dehydrogenase(DHODH) is a viable target for the development of therapeutics to treat cancer andimmunological diseases, such asrheumatoid arthritis(RA), psoriasis andmultiple sclerosis(MS).
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
Highlights from today's headlines include the latest political developments surrounding health reform as well as news about California's health insurance premium rates.
An innovative new medical program in Queensland will use the latest technology to help treat children living in remote Indigenous communities.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Human dihydroorotate dehydrogenase(DHODH) is a viable target for the development of therapeutics to treat cancer andimmunological diseases, such asrheumatoid arthritis(RA), psoriasis andmultiple sclerosis(MS).
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
Highlights from today's headlines include the latest political developments surrounding health reform as well as news about California's health insurance premium rates.
An innovative new medical program in Queensland will use the latest technology to help treat children living in remote Indigenous communities.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 3 |
| Total Amount of Fines in Dollars | $23847 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 33.75 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.28 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.66 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.7 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.41 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 5.24 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.12 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 62.92 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.26 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 46.28 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.59 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 37.19 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.07 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.78 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 89.59 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 61.19 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 55.86 | 82.93 |
News Archive
Human dihydroorotate dehydrogenase(DHODH) is a viable target for the development of therapeutics to treat cancer andimmunological diseases, such asrheumatoid arthritis(RA), psoriasis andmultiple sclerosis(MS).
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
Highlights from today's headlines include the latest political developments surrounding health reform as well as news about California's health insurance premium rates.
An innovative new medical program in Queensland will use the latest technology to help treat children living in remote Indigenous communities.
› Verified 8 days ago
Hillcrest Convalescent Center Location: 1417 W Pettigrew Street, Durham, North Carolina 27705 Phone: (919) 286-7705 | |
Pettigrew Rehabilitation Center Location: 1515 W Pettigrew Street, Durham, North Carolina 27705 Phone: (919) 286-0751 | |
Durham Nursing & Rehabilitation Center Location: 411 S Lasalle Street, Durham, North Carolina 27705 Phone: (919) 383-5521 | |
Accordius Health At Rose Manor Llc Location: 4230 North Roxboro Street, Durham, North Carolina 27704 Phone: (919) 477-9805 | |
Brian Center Southpoint Location: 6000 Fayetteville Road, Durham, North Carolina 27713 Phone: (919) 544-9021 |